Source notes

Claims about active food peptides raise a basic question: can those small protein fragments reach the places where they are supposed to work? This paper examines evidence for intact peptide absorption in healthy adults. Two- and three-amino-acid fragments readily enter intestinal cells, but many are broken down there before reaching the blood. Evidence for meaningful absorption of larger fragments is much less convincing. In one human study using enriched yoghurt, measured blood levels of a milk-derived peptide were about a thousand times below the concentration needed to inhibit its proposed target enzyme in laboratory tests.

Finding a peptide in blood does not by itself establish a useful biological effect. The amount, timing, survival in circulation, and access to its target all matter. Equally, weak evidence for absorption does not prove that every food peptide is inactive. Some may act within the gut or trigger signals from its surface without needing to circulate intact throughout the body.

How Does This Show Up in Real Life?

A claim that a food contains a peptide with a laboratory effect leaves several steps unanswered. Digestion may destroy the fragment, intestinal cells may break it down, or the amount reaching blood may be too small to reproduce the experiment. Those questions are particularly relevant when a food or supplement is described as acting like an injected peptide or a drug. Injection bypasses the digestive barriers that an ordinary meal must pass. The paper also distinguishes normal nutrient absorption from the tiny amounts of protein material sampled by the immune system. That sampling is not evidence that a large effective dose reaches other organs. This research helps readers assess how a claim is supported; it does not establish that protein foods should be avoided or that a particular supplement works.

Much of the evidence comes from laboratory preparations, animals, newborns, or people with intestinal disease, which cannot simply represent healthy adults. Some experiments used unrealistic concentrations or bypassed digestion. Detecting very small peptide quantities is technically difficult, and rapid breakdown can complicate measurements. The authors identify a need for stronger human evidence linking absorption, circulating amounts, and actual physiological effects.

Treat this source as a careful check on the steps between a laboratory observation and a health claim. A proposed action needs evidence of delivery as well as activity. The remaining uncertainty concerns which peptides matter, in what amounts, and under which conditions.